[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100627415":3},{"organization":4,"outcomesModule":7,"designInfo":32,"detailedDescription":35,"studyPopulation":36,"armGroups":31,"interventions":31,"overallOfficials":31,"centralContacts":37,"locations":43,"responsibleParty":66,"collaborators":31,"id":69,"slug":70,"hasResults":71,"nctId":72,"briefTitle":73,"officialTitle":74,"acronym":31,"eligibilityCriteria":75,"healthyVolunteers":71,"sex":76,"minAge":77,"maxAge":31,"enrollmentInfo":78,"targetDuration":31,"studyType":81,"phases":31,"briefSummary":82,"conditions":83,"keywords":88,"overallStatus":93,"whyStopped":31,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":95,"startDateStruct":98,"completionDateStruct":100,"leadSponsor":102,"locationsCount":103},{"fullName":5,"class":6},"Caja Costarricense de Seguro Social","OTHER_GOV",{"primaryOutcomes":8,"secondaryOutcomes":19,"otherOutcomes":31},[9,13,16],{"measure":10,"description":11,"timeFrame":12},"Prevalence of Metabolic Comorbidities in Patients With Psoriasis","Proportion (%) of patients with documented diagnosis of obesity (BMI ≥30 kg\u002Fm²), diabetes mellitus (prior diagnosis or HbA1c ≥6.5%), hypertension (prior diagnosis or BP ≥140\u002F90 mmHg), dyslipidemia (prior diagnosis or abnormal lipid profile), and metabolic syndrome.","2024-2025",{"measure":14,"description":15,"timeFrame":12},"Prevalence of Atherosclerotic Cardiovascular Disease","Proportion (%) of patients with documented history of coronary artery disease, myocardial infarction, angina\u002Frevascularization, ischemic stroke, or peripheral arterial disease.",{"measure":17,"description":18,"timeFrame":12},"Prevalence of Psoriatic Arthritis","Proportion (%) of patients with rheumatologist-confirmed diagnosis of psoriatic arthritis, including characterization of predominant clinical domain (peripheral arthritis, axial involvement, enthesitis, dactylitis).",[20,23,25,28],{"measure":21,"description":22,"timeFrame":12},"Psoriasis Severity","Psoriasis Area and Severity Index (PASI), continuous score (0-72), categorized as mild (\\\u003C10), moderate (10-20), or severe (\\>20).",{"measure":21,"description":24,"timeFrame":12},"Body Surface Area (BSA) Affected, percentage of body surface area affected by psoriasis",{"measure":26,"description":27,"timeFrame":12},"Association Between Psoriasis Severity and Comorbidities","Statistical association between severity categories and presence of metabolic comorbidities, atherosclerotic disease, and psoriatic arthritis using chi-square, Fisher's exact test, t-test or Mann-Whitney U test.",{"measure":29,"description":30,"timeFrame":12},"Inflammatory and Metabolic Biomarkers","Continuous values of C-reactive protein, erythrocyte sedimentation rate, neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, monocyte-to-lymphocyte ratio, cardiac troponin, B-type natriuretic peptide, total cholesterol, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, triglycerides, fasting plasma glucose, glycated hemoglobin, serum creatinine, estimated glomerular filtration rate, aspartate aminotransferase, alanine aminotransferase, alkaline phosphatase, and total bilirubin.",null,{"allocation":31,"interventionModel":31,"interventionModelDescription":31,"primaryPurpose":31,"observationalModel":33,"timePerspective":34,"maskingInfo":31},"COHORT","RETROSPECTIVE","Psoriasis is a chronic immune-mediated inflammatory dermatosis with variable severity, systemic associations, and substantial quality-of-life impact. Although multiple topical, phototherapy, systemic, and biologic treatments are available, real-world epidemiologic and therapeutic data in Costa Rica remain limited. This study is a retrospective observational characterization of psoriasis patients treated between 2024 and 2025. Unlike interventional trials evaluating specific drugs or prospective registries of targeted therapies, this study analyzes existing clinical records to describe demographic distribution, clinical subtypes, severity (PASI\u002FBSA\u002FDLQI), comorbidities, and treatment patterns across routine care. It does not introduce therapeutic modifications or standardized follow-up, but reflects real-world management decisions across disease severities. By capturing population-level data on psoriasis presentation and treatment in Costa Rica, the study provides baseline national evidence distinct from drug-specific or interventional psoriasis studies.","The study population comprises adolescents and adults (≥12 years) with a confirmed diagnosis of psoriasis documented in the Electronic Health Record (EHR-EDUS) of Hospital Calderón Guardia who were evaluated in outpatient dermatology or rheumatology clinics between 2024 and 2025. Eligible patients received systemic therapy and\u002For phototherapy for psoriasis and had sufficient clinical information to assess disease severity, metabolic comorbidities, atherosclerotic cardiovascular disease, and psoriatic arthritis. This hospital-based cohort reflects real-world patients with moderate-to-severe psoriasis managed in specialized care within the Costa Rican public health system during the study period.",[38],{"name":39,"role":40,"phone":41,"phoneExt":31,"email":42},"Daniel E Barquero-Orias, Dermatologist","CONTACT","+506 83411026","debarque@ccss.sa.cr",[44],{"facility":45,"status":31,"city":46,"state":47,"zip":48,"country":49,"countryCode":50,"cosmosGeoPoint":51,"geoPoint":56,"contacts":57},"Caja Costarricense del Seguro Social","San José","Provincia de San José","40901","Costa Rica","CR",{"type":52,"coordinates":53},"Point",[54,55],-84.08489,9.93388,{"lat":55,"lon":54},[58,59,61,63],{"name":39,"role":40,"phone":41,"phoneExt":31,"email":42},{"name":39,"role":60,"phone":31,"phoneExt":31,"email":31},"SUB_INVESTIGATOR",{"name":62,"role":60,"phone":31,"phoneExt":31,"email":31},"Benjamin Hidalgo-Matlock, Dermatologist",{"name":64,"role":65,"phone":31,"phoneExt":31,"email":31},"Pamela Cambronero-Ulate, Dermatology Resident","PRINCIPAL_INVESTIGATOR",{"type":65,"investigatorFullName":67,"investigatorTitle":68,"investigatorAffiliation":5,"oldNameTitle":31,"oldOrganization":31},"Daniel Barquero Orias","Sub-Investigator","100627415","psoriasis-comorbidities-at-hospital-caldern-guardia-100627415",false,"NCT07448337","Psoriasis Comorbidities at Hospital Calderón Guardia","Prevalence of Metabolic Comorbidities, Atherosclerotic Arterial Disease, and Psoriatic Arthritis in Patients With Psoriasis and Their Association With Clinical Severity and Therapeutic Profile Among Patients Treated at Hospital Rafael Ángel Calderón Guardia During 2024-2025","Inclusion Criteria:\n\n* Patients evaluated in outpatient clinics during the period 2024-2025.\n* Patients receiving systemic therapy and\u002For phototherapy.\n* Patients aged 12 years or older, of any sex.\n* Availability of sufficient clinical information to assess psoriasis severity, metabolic comorbidities, atherosclerotic cardiovascular disease, and psoriatic arthritis.\n* At least one dermatologic or rheumatologic evaluation recorded in the Electronic Health Record (EHR-EDUS) during the study period.\n* Confirmed diagnosis of psoriasis documented in the Electronic Health Record (EHR-EDUS) of Hospital Calderón Guardia.\n\nExclusion Criteria:\n\n* Clinical records insufficient to evaluate psoriasis severity, comorbidities, or therapeutic profile.\n* Patients managed exclusively with topical therapies.\n* Duplicate or inconsistent records, preventing accurate patient classification.\n* Cutaneous conditions not compatible with psoriasis.","ALL","12 Years",{"count":79,"type":80},350,"ESTIMATED","OBSERVATIONAL","The goal of this observational study is to characterize the epidemiologic, clinical, severity, and therapeutic features of patients with psoriasis treated in Costa Rica between 2024 and 2025. The main questions it aims to answer are:\n\nWhat are the demographic and clinical characteristics and severity profiles of psoriasis patients?\n\nWhat treatments are used in routine clinical practice, and how are they associated with disease severity and outcomes?\n\nPatients with psoriasis receiving dermatologic care during the study period will be included. Data will be obtained retrospectively from electronic medical records and clinical registries without intervention or modification of treatment.",[84,85,86,87],"Psoriasis","Psoriasis Arthritis","Psoriasis (PsO)","Psoriasis Patients",[89,49,84,90,91,92],"Comorbidities","Real-world data","Disease severity","Epidemiology","NOT_YET_RECRUITING","2026-04-02",{"date":96,"type":97},"2026-04-08","ACTUAL",{"date":99,"type":80},"2026-05",{"date":101,"type":80},"2027-05",{"name":5,"class":6},1]